Physician profile
John A Dooley
NPI 1467431155
$877.90
in general payments reported to CMS, 2019-2025
12 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.17 · 2024: $536 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $230.22 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $199.32 | 2024 | Zepbound, Mounjaro |
| Pfizer INC. | $146.02 | 2024-2025 | |
| Novo Nordisk INC | $86.86 | 2024-2025 | Wegovy, Ozempic |
| Sumitomo Pharma America, INC. | $56.86 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $33.94 | 2024 | Quviviq |
| Daiichi Sankyo INC. | $33.17 | 2021 | |
| Heartflow, INC. | $22.87 | 2024 | |
| Astellas Pharma US INC | $22.59 | 2024 | Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $18.13 | 2024 | Eliquis |
| Abbvie INC. | $14.51 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.41 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.